BioCryst nods goalward to pharma partner, but M&A gets red card
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals believes it has a shot at the competitive gout market, based on positive Phase IIb data from the extension study for its novel oral drug ulodesine (BCX4208), but it needs a pharmaceutical partner to finish off the move.